"Heartburn"

Treating heartburn and dyspepsia during breastfeeding SPS - Specialist Pharmacy ServiceAbout Log in RegisterNHSGuidanceEventsPlanningTrainingPublicationsTools SearchCOVID-19PGDsAdministeringCautions and contraindicationsDosingDeprescribingMore Treating heartburn and dyspepsia during breastfeedingPublished 5 March 2024Topics: Aluminium hydroxide · Calcium carbonate · Calcium carbonate + Sodium and to apply the principles of prescribing in breastfeeding when looking at the available information and making treatment decisions.RecommendationsWe provide a summary of the recommendations by mechanism of action.Antacid and alginate preparationsThere is extensive experience of use of antacids during breastfeeding and they are considered first-line options for managing heartburn or dyspepsia.Alginates

An innovative swallowable sponge detects Barrett's oesophagus in people with heartburn, study shows An innovative swallowable sponge detects Barrett's oesophagus in people with heartburn, study showsAn innovative swallowable sponge detects Barrett's oesophagus in people with heartburn, study shows Skip to content * Accessibility options: * * Search articles Evidence * About Us * Browse next?You may be interested to readMenu * About Us * Browse content * Become a reviewer * Newsletter Sign Up * Contact us * Homepage * > * Alert * > * An innovative swallowable sponge detects Barrett's oesophagus in people with heartburn, study shows An innovative swallowable sponge detects Barrett's oesophagus in people with heartburn, study showsDetection, Screening and Diagnosis 16.02.21 doi

Heartburn and Dyspepsia: treatment during pregnancy Heartburn and Dyspepsia: treatment during pregnancy – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice SPS - Specialist Pharmacy Service The first stop for professional medicines advice * About * Log in * Register NHS * Guidance Guidance * Guidance index * COVID-19 * PGDs * Manufacturing and preparation * Unlicensed medicines * Homecare * ATMPs * Clinical Trials * Medical gases * More * Less * Home * Guidance * Safety in pregnancy Heartburn and Dyspepsia: treatment during pregnancy Paula Russell, Principal Pharmacist, Regional Drug and Therapeutics Centre (Newcastle Upon Tyne) · Published 6 January 2022 Topics: Gastrointestinal disorders · Safety

Nonprescription Heartburn Medications for Adults. This JAMA Patient Page describes the types of nonprescription heartburn medications: antacids, histamine 2 blockers, and proton pump inhibitors.

Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial In the treatment of upper GI endoscopy-negative patients with heartburn and epigastric pain or burning, antacids, anti-reflux agents, and mucosal protective agents (MPA) are widely used, alone or as add-on treatment to increase response to proton pump inhibitors, which are not indicated in infancy and pregnancy, and account for significant cost expenditure. In this randomized, controlled, double-blind, double-dummy, multicenter trial assessing the efficacy and safety of MPA Poliprotect (neoBianacid®) versus Omeprazole in the relief of heartburn and epigastric pain/burning, 275 endoscopy-negative outpatients were given

BEHAVIORAL THERAPY FOR FUNCTIONAL HEARTBURN: Recommendation Statements. Brain-gut behavior therapies (BGBT) are increasingly recognized as effective therapeutic interventions for functional heartburn. However, recommendations regarding candidacy for treatment, initial treatment selection, and navigating treatment non-response have not been established for functional heartburn specifically . The aim of this study was to establish expert-based recommendations for behavioral treatment in patients with functional heartburn. The validated RAND/University of California, Los Angeles Appropriateness Method was applied to develop recommendations. A 15-member panel composed of 10 gastrointestinal psychologists and 5 esophageal specialists ranked the appropriateness of a series of statements on a 9

Heartburn Relief is the Major Unmet Need for Drug Development in Gastroesophageal Reflux Disease: Threshold Value Analysis. Heartburn symptoms contribute to healthcare-seeking among patients with gastroesophageal reflux disease (GERD). Despite clinical guidance, management is often dictated by insurance restrictions. Several potassium-competitive acid blockers (PCAB) are under development , and no treatment over a one-year time horizon. Clinical responses were evaluated based on the proportions of heartburn-free days in a recent phase 3 multicenter trial. Healthcare utilization for persistent reflux symptoms was derived from national observational studies compared to healthy controls. Costs and quality-adjusted life years [QALY] were reported. Without insurance coverage for appropriate therapy

VONOPRAZAN IS EFFICACIOUS FOR TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL. Potassium-competitive acid blockers have documented efficacy for erosive esophagitis. We performed a randomized trial in U.S. subjects diagnosed with non-erosive reflux disease (NERD) of vonoprazan vs. placebo for 4 weeks followed by a 20-week active-treatment extension. Adult subjects with heartburn ≥4 days/week during screening without erosive esophagitis on endoscopy were randomized to placebo, vonoprazan 10mg, or vonoprazan 20mg. After 4 weeks, subjects on placebo were re-randomized to vonoprazan 10 or 20mg and those already on vonoprazan continued at the same dose for 20 weeks. Electronic diaries were completed twice daily. The primary endpoint was percentage of days without daytime

Psychological processes, not physiological parameters, are most important contributors to symptom severity in patients with refractory heartburn/regurgitation symptoms.

Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial. Patients with gastroesophageal reflux disease (GERD) frequently experience nighttime heartburn and sleep disturbance. Tegoprazan is a new potassium-competitive acid blocker that can rapidly block acid secretion. This study aims to evaluate the efficacy of tegoprazan compared with esomeprazole in relieving nighttime heartburn and sleep disturbances. Patients with erosive esophagitis, nighttime heartburn, and sleep disturbances were randomized to receive tegoprazan 50 mg or esomeprazole 40 mg for 2 weeks. The primary endpoint was time to first nighttime heartburn-free interval. The percentage of nighttime heartburn-free

Heartburn relief with bicarbonate-rich mineral water: results of the randomised, placebo-controlled phase-III trial STOMACH STILL. We assessed whether the bicarbonate-rich mineral water Staatl. Fachingen STILL is superior over conventional mineral water in relieving heartburn. Multicentre, double-blind, randomised, placebo-controlled trial STOMACH STILL in adult patients with frequent heartburn episodes since ≥6 months and without moderate/severe reflux oesophagitis. Patients drank 1.5 L/day verum or placebo over the course of the day for 6 weeks. Primary endpoint was the percentage of patients with reduction of ≥5 points in the Reflux Disease Questionnaire (RDQ) score for 'heartburn'. Secondary endpoints included symptom reduction (RDQ), health-related quality of life (HRQOL, Quality of Life

Optimizing the management algorithm for heartburn in general gastroenterology: Cost-effectiveness and cost-minimization analysis. Heartburn is the most common symptom seen in gastroenterology practice. We aimed to optimize cost-effective evaluation and management of heartburn. We developed a decision analytic model from insurer and patient perspectives comparing four strategies for patients with a trial of PPI discontinuation was the most effective of all strategies (gaining 22 healthy days/year) and saved $2,183 to insurers and $2,396 to patients. Among patients with heartburn, endoscopy with ambulatory reflux monitoring (OFF-PPI) optimizes cost-effective management by matching treatment to phenotype. When erosive findings are absent, trialing PPI discontinuation is more cost-effective than

Interventions for heartburn in pregnancy. Heartburn is one of the most common gastrointestinal symptoms in pregnant women. It can occur in all trimesters of pregnancy. The symptoms of heartburn in pregnancy may be frequent, severe and distressing, but serious complications are rare. Many interventions have been used for the treatment of heartburn in pregnancy. These interventions include advice on diet, lifestyle modification and medications. However, there has been no evidence-based recommendation for the treatment of heartburn in pregnancy. To assess the effects of interventions for relieving heartburn in pregnancy. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 June 2015), ClinicalTrials.gov (2 March 2015), Asian & Oceanic Congress of Obstetrics & Gynaecology

Applying Lyon Consensus criteria in the work-up of patients with proton pump inhibitory-refractory heartburn. A hierarchical approach for gastro-oesophageal reflux disease (GERD) diagnosis by impedance-pH monitoring was proposed by the Lyon Consensus, based on acid exposure time (AET) and supportive impedance metrics. To establish the clinical value of Lyon Consensus criteria in the work-up of patients with proton pump inhibitory (PPI)-refractory heartburn. Expert review of off-therapy impedance-pH tracings from unproven GERD patients with PPI-refractory heartburn prospectively evaluated at referral centers. Impedance metrics, namely total reflux episodes, postreflux swallow-induced peristaltic wave index, and mean nocturnal baseline impedance, were assessed. Expert review of on-therapy

Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. Gastroesophageal reflux disease (GERD) is one the most common medical complaints in pregnant women. Some women continue to experience GERD symptoms after delivery. Effective management of GERD symptoms is important to improve productivity and quality of life. Management of heartburn in pregnant

Limitations of Heartburn and Other Societies' Criteria in Barrett's Screening for Detecting De Novo Esophageal Adenocarcinoma. Despite extensive Barrett's esophagus (BE) screening efforts, most patients with esophageal adenocarcinoma (EAC) present de novo. It is unclear how much of this problem is the result of insensitivity or poor applications of current screening guidelines. We aimed as appropriate. In the Mayo clinic cohort there were 54.9% EAC cases and in the UK cohort there were 38.9% EAC cases that were not identified by ACG or BSG screening criteria, respectively. Among patients who did not meet the screening criteria, lack of heartburn was observed in 86.5% in the Mayo clinic cohort and in 61.4% in the UK cohort. Other risk factors that were lacking included obesity (defined

Recent insights on functional heartburn and reflux hypersensitivity. Rome IV experts have proposed that gastroesophageal reflux disease (GERD) should be diagnosed only in patients with abnormal esophageal acid exposure, and that reflux hypersensitivity (RH) and functional heartburn (FH) both should be considered functional conditions separate from GERD. Although past and recent evidence support modulators and good results of antireflux surgery for RH support recategorization of RH within the GERD world. Further research is needed to correctly phenotype patients who have heartburn without mucosal breaks, and to guide their effective management.

Higher Carbohydrate Amount and Lower Glycemic Index Increase Hunger, Diet Satisfaction, and Heartburn in Overweight and Obese Adults in the OmniCarb Randomized Clinical Trial. The Dietary Approaches to Stop Hypertension (DASH) diet, a high-carbohydrate diet, is highly recommended based on its cardiovascular risk benefits, yet adherence remains persistently low. How subjective impressions /loose stools, constipation, bloating, nausea, and heartburn). Participant mean age was 52 y, with 52% women, 51% non-Hispanic black, and 56% obese (BMI ≥30). Compared with baseline, all intervention diets decreased heartburn, increased diarrhea/loose stools, and increased bloating, but did not significantly affect constipation or nausea. Compared with lower carbohydrate diets, higher carbohydrate

Treatment of long-term heart burn Frequently AskedQuestions ↓Proton pump inhibitor medication (PPI)Laparoscopic surgery (also known as keyhole surgery) Why would I be offered this treatment?If you have long-term heartburn lasting longer than 4 weeks, one possible treatment is to use medication called proton pump inhibitors (PPI).If treatment with PPI medication is not working or giving you is not usually needed after surgery.How long will it take for the treatment to work?Most people’s symptoms improve after a few days of starting this medication.Most people’s symptoms improve soon after surgery. Swallowing might be uncomfortable for a few weeks, but this goes away.Will my symptoms get better?Heartburn symptoms get better in 60 to 90 in every 100 people (60–90%), but symptoms continue or come

Option grid to help people make decisions about long term heartburn treatment Frequently AskedQuestions ↓Proton pump inhibitor medication (PPI)Laparoscopic surgery (also known as keyhole surgery) Why would I be offered this treatment?If you have long-term heartburn lasting longer than 4 weeks, one possible treatment is to use medication called proton pump inhibitors (PPI).If treatment with PPI . It takes a week or so to recover. Medication is not usually needed after surgery.How long will it take for the treatment to work?Most people’s symptoms improve after a few days of starting this medication.Most people’s symptoms improve soon after surgery. Swallowing might be uncomfortable for a few weeks, but this goes away.Will my symptoms get better?Heartburn symptoms get better in 60 to 90 in every